Cannon Global Investment Management LLC Invests $530,000 in Kiniksa Pharmaceuticals International, plc $KNSA

Cannon Global Investment Management LLC acquired a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the first quarter, according to the company in its most recent filing with the SEC. The firm acquired 11,000 shares of the company’s stock, valued at approximately $530,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 18.2% during the 1st quarter. SG Americas Securities LLC now owns 640,179 shares of the company’s stock valued at $30,825,000 after acquiring an additional 98,783 shares during the period. Virtu Financial LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter valued at $267,000. Invesco Ltd. lifted its position in shares of Kiniksa Pharmaceuticals International by 25.9% during the fourth quarter. Invesco Ltd. now owns 32,334 shares of the company’s stock valued at $1,334,000 after purchasing an additional 6,656 shares in the last quarter. Mercer Global Advisors Inc. ADV lifted its position in shares of Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after buying an additional 508 shares in the last quarter. Finally, Empowered Funds LLC bought a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth $51,000. Institutional investors own 53.95% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on KNSA shares. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Wednesday, April 29th. Citigroup lifted their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Zacks Research raised shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Jefferies Financial Group raised their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. Finally, Weiss Ratings downgraded Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $60.86.

Kiniksa Pharmaceuticals International Trading Up 4.1%

NASDAQ:KNSA opened at $59.20 on Friday. The company has a 50-day moving average price of $52.17 and a 200-day moving average price of $46.95. The stock has a market cap of $4.55 billion, a price-to-earnings ratio of 65.78 and a beta of 0.12. Kiniksa Pharmaceuticals International, plc has a 12 month low of $26.27 and a 12 month high of $61.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.09. The company had revenue of $214.27 million for the quarter, compared to analysts’ expectations of $206.11 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Kiniksa Pharmaceuticals International’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.11 earnings per share. Equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CAO Michael R. Megna sold 6,625 shares of the firm’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the transaction, the chief accounting officer owned 27,418 shares in the company, valued at $1,280,146.42. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Sanj K. Patel sold 483,654 shares of the company’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total value of $25,082,296.44. Following the completion of the sale, the chief executive officer directly owned 431,904 shares in the company, valued at approximately $22,398,541.44. The trade was a 52.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 653,301 shares of company stock worth $34,046,073. 51.98% of the stock is owned by insiders.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.